TD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)
TD Cowen analyst Ritu Baral maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of ...
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% on Insider Selling
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) were down 6.8% during trading on Monday after an insider sold shares in the company. The company traded as low as $322.44 and ...
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Guardant Health (GH – Research Report), ...
Research Analysts Set Expectations for MDGL Q1 Earnings
Analysts at B. Riley raised their Q1 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued on Thursday, February 27th. B. Riley analyst M. Mamtani now expects that ...
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...
Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA
BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture?
Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.